REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $35.27.

A number of research analysts have issued reports on the company. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright dropped their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday. Finally, Barclays dropped their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th.

REGENXBIO Stock Up 4.5 %

Shares of RGNX opened at $9.59 on Friday. The company has a 50-day moving average price of $10.24 and a two-hundred day moving average price of $12.07. The stock has a market cap of $475.09 million, a price-to-earnings ratio of -1.91 and a beta of 1.23. REGENXBIO has a 12 month low of $8.53 and a 12 month high of $28.80.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in REGENXBIO during the 1st quarter worth approximately $56,000. nVerses Capital LLC grew its holdings in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares in the last quarter. Finally, Diversified Trust Co acquired a new stake in REGENXBIO in the second quarter worth $121,000. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.